Video

Spesolimab for Treatment of GPP

Author(s):

Raj Chovatiya, MD, PhD,Boni Elewski, MD

Experts discuss spesolimab, an IL-36 inhibitor, that was recently FDA approved for treatment of GPP.

Related Videos
Skin of Color Savvy: The Art and Science of Treating Patients of Color
Crisis Point: Benzene Concerns in Acne Care
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
Related Content
Study Highlights Findings on Chronic Hand Eczema from Skin Tape Stripping
January 10th 2025

Study Highlights Findings on Chronic Hand Eczema from Skin Tape Stripping

Tim Smith
Skin of Color Savvy: Itch in Skin of Color, with Andrew Alexis, MD, MPH, and Shawn Kwatra, MD
January 6th 2025

Skin of Color Savvy: Itch in Skin of Color, with Andrew Alexis, MD, MPH, and Shawn Kwatra, MD

Andrew F Alexis, MD, MPH Shawn Kwatra, MD
New Phase 2a Findings Released on IMG-007 Treatment of Atopic Dermatitis
January 9th 2025

New Phase 2a Findings Released on IMG-007 Treatment of Atopic Dermatitis

Tim Smith
The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD
November 18th 2024

The Medical Sisterhood: Role Models and Mentorship, with Susan Taylor, MD, and Linda Stein Gold, MD

Mona Shahriari, MD, FAAD Linda Stein Gold, MD Susan Taylor, MD
C-Reactive Protein Effective as Biomarker for HS Treated with Adalimumab
January 8th 2025

C-Reactive Protein Effective as Biomarker for HS Treated with Adalimumab

Tim Smith
Global Atopic Dermatitis Among Children Projected to Rise Over 50 Years
January 8th 2025

Global Atopic Dermatitis Among Children Projected to Rise Over 50 Years

Tim Smith
© 2025 MJH Life Sciences

All rights reserved.